Amgen Boasts Lucrative Acquisitions, Drug Updates, Burgeoning Biosimilars at JPM

Not even a month after purchasing rare disease company Horizon Therapeutics Amgen came to the 41st J.P. Morgan Healthcare Conference in San Francisco to tout more than just this feather in its hat.

In a presentation led by Robert J. Bradway, Amgen chairman and chief executive officer, the company covered recent acquisitions, Repatha and Lumakras updates, biosimilars and its broader financial outlook.